CAPLIPOINT

acquired 10 approved ANDAs for injectable and ophthalmic products from a multinational generic drug manufacturer, strengthening its US presence. The addressable market is $473.2 mn, and the acquired portfolio includes select oncology injectables. Revenue grew 10.6% to ₹534 crore in the September quarter.